Clinical Trial

EDETEK Recognized as the highest Major Contender in Everest Group’s 2024 Clinical Data and Analytics Platforms PEAK Matrix® Assessment

PRINCETON, N.J., Nov. 13, 2024 /PRNewswire/ -- EDETEK, Inc., a leading global provider of specialized software and services for the…

2 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial --…

2 months ago

Tenon Medical Reports Third Quarter 2024 Financial Results

~ 3Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3%…

2 months ago

Revolutionizing Heart Health: Frontier X Plus Gains FDA Clearance

NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Fourth Frontier, a medical technology company based out of New York and Bangalore,…

2 months ago

Revolutionizing Disease Detection with Point-of-Care Health Screenings: Vitazi.ai Leads in Oculomics

SANTA FE, N.M., Nov. 13, 2024 /PRNewswire/ -- Vitazi.ai, a leader in the field of oculomics, is transforming healthcare with an…

2 months ago

Subtle Medical Unveils Subtle-ELITE and New Strategic Partnerships at RSNA 2024

Subtle's Latest Solutions and Partnerships Set New Benchmarks for AI-powered Acceleration and Image Quality MENLO PARK, Calif., Nov. 13, 2024…

2 months ago

C-Path Announces Gender Equitable Medicines for Parkinson’s Disease (GEM-PD) Initiative

C-Path expands its worldwide leadership in accelerating drug development in neurology; seeks additional collaborators to broaden impact. TUCSON, Ariz., Nov.…

2 months ago

Ethics Board Approval Granted for Lexaria’s 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp.…

2 months ago

Jaguar Health Reports Third Quarter 2024 Financial Results

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately…

2 months ago